Progress of immune-targeted therapy drugs for advanced mycosis fungoides/Sézary syndrome
10.3760/cma.j.cn115356-20240104-00004
- VernacularTitle:晚期蕈样霉菌病/Sézary综合征免疫靶向治疗药物的新进展
- Author:
Liping XIAO
1
;
Jia FENG
Author Information
1. 北京大学深圳医院血液内科，深圳 518036
- Keywords:
Primary cutaneous T-cell lymphoma;
Immune-targeted drugs;
Chimeric antigen receptors T-cell therapy
- From:
Journal of Leukemia & Lymphoma
2024;33(10):636-640
- CountryChina
- Language:Chinese
-
Abstract:
Primary cutaneous T-cell lymphoma (CTCL) is the most common malignant proliferative disease of mature memory T cells, and the most common subtype is mycosis fungoides/Sézary syndrome. The local treatment in the skin is mainly given in patients with early CTCL and good prognosis can be achieved generally, while for patients in advanced stage, there is no standard recommended treatment regimen due to the poor efficacy of traditional therapy. In recent years, with the development of immune-targeted drugs for T-cell lymphoma, a variety of new drugs have shown good efficacy in the clinical treatment of CTCL, including histone deacetylase inhibitors, monoclonal antibodies, chimeric antigen receptors T-cell therapy. This paper reviews the research progress of immune-targeted therapy drugs for advanced mycosis fungoides/Sézary syndrome.
